Convano Strengthens Medical AI Division with New Executive Appointments

Convano Enhances AI Division with New Leadership

In a significant move to bolster its AI-related initiatives, Convano, headquartered in Shibuya, Tokyo, has appointed Shohei Nambu and Hiroki Nakamura as executive officers responsible for its AI operations, effective September 1, 2026. This strategic appointment follows the company’s goal to strengthen the development and execution of its specialized medical AI agent system, AXON.

Both Nambu and Nakamura are not new to the AXON project; they have previously contributed their medical expertise as external collaborators in its planning and development stages. Their transition into executive roles is seen as a way to further integrate clinical insights into AI development, enhancing the operational framework that supports healthcare institutions.

Nambu and Nakamura: Experienced Medical Professionals

Shohei Nambu

Graduated from Shinshu University School of Medicine, Dr. Nambu pursued his postgraduate studies at the University of Tokyo, focusing on Neurology, and earned a Doctorate in Medicine. He is a licensed specialist in neurosurgery, vascular therapy, and neuro-endoscopy. In 2024, he will also take on the role of Director at Alpaca Family Clinic and serve as the CEO of SeaTurtle, Inc.

Role	Appointment Date
--	------
Executive Officer (AI Operations)	September 1, 2026

Hiroki Nakamura

Similarly, Dr. Nakamura graduated from Shinshu University and has a robust background in plastic and aesthetic surgery, currently practicing at the Zenith Beauty Clinic in Ginza. He has been engaged in the joint development of the AXON AI system since late 2025, focusing on backend development including system integration, automation, and security protocols.

Role	Appointment Date
--	------
Executive Officer (AI Operations)	September 1, 2026

Strengthening the AXON Initiative

The appointment of these two physicians to the executive board represents a pivotal shift in Convano's operational approach towards its AI initiatives. By embedding experienced medical professionals within its executive leadership, Convano aims to refine its development strategies for AXON and other AI projects. The company's intention is to merge extensive medical knowledge with advanced AI technologies to enhance the efficiency of healthcare procedures.

This reorganization does not entail significant additional costs and is aimed solely at reinforcing the existing management structure. As a result, the impact on Convano’s consolidated financial performance for the fiscal year ending March 2027 is projected to be minimal.

About Convano

Convano Inc. operates under the corporate philosophy of “Creation Of New Value And New Opportunities,” focusing on AI and digital transformation (DX) consulting services that support business growth and operational change. The firm leverages its extensive experience in business administration and data utilization to provide AI system development, implementation support, and marketing consultancy within various sectors, especially in healthcare. Additionally, it runs the FASTNAIL nail service chain, applying real-world insights to strengthen its position in practical solution delivery, driving sustainable corporate value.